Clinical benefits of biochemical markers of bone turnover in Egyptian children with chronic liver diseases

Table 2 Liver function tests in different patient groups and control group (mean ± SE)

	Control	Bilharziasis	HBV	HCV
	(n = 30)	(n = 9)	(n = 12)	(n = 29)
ALT	20.5 ± 0.9	38.0 ± 6.8a	72.6 ± 12.4a	107.0 ± 28.1a
(U/L)
AST	18.4 ± 0.8	46.0 ± 7.5a	71.2 ± 10.8a	120.0 ± 21.8a
(U/L)
ALP	74.0 ± 9.3	82.0 ± 11.8	214.0 ± 41.2a	165.0 ± 28.9a
(U/L)
GGT	26.0 ± 2.1	37.6 ± 9.9	54.0 ± 1.5a	59.9 ± 11.1a
(U/L)
T. bilirubin	0.84 ± 0.03	0.9 ± 0.16	1.8 ± 0.20a	1.3 ± 0.13a
(mg/dL)
T. protein	6.9 ± 0.10	7.1 ± 0.30	6.8 ± 0.20	6.7 ± 0.10a
(mg/dL)
Albumin	4.0 ± 0.06	3.9 ± 0.10	3.5 ± 0.19a	3.6 ± 0.10a
(mg/dL)
Prothrombin	93.0 ± 1.3	77.0 ± 4.0a	69.0 ± 6.0a	65.6 ± 2.50a
(%)

^aP < 0.05 vs control group.